Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MOR106 multiple ascending subcutaneous doses in Japanese adults with moderate to severe atopic dermatitis
jRCT2080224787Phase 2Terminated
- Sponsor
- Galapagos NV
- Start
- Jul 2019
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in atopic dermatitis (AD) comparing MOR106 with Placebo (2 arms). Primary endpoints: Safety and tolerability of multiple ascending doses of MOR106 and Pharmacokinetics of multiple ascending doses of MOR106. Started Jul 2019; status: terminated.
02
Drugs
MOR106
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on jRCT2080224787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224787.